- Aurobindo Pharma completes acquisition of 51% stake in GLS Pharma.
- Lupin and I’rom enter into exclusive licensing agreement for Denosumab biosimilar in Japan.
- Dr Reddy's, Aurigene Pharma ink MoU with DNDi to develop drugs for NTDs.
- India, UK based Anuva ties up with US genomics major
- Eris Lifesciences enters licensing deal with Biocon for insulin glargine
- Sonde Health inks multi-year partnership with Koye Pharma.
- AstraZeneca India announced its partnership with Alveofit, to offer IoT-enabled handheld spirometers at hospitals across the country.
- LumaBridge inks deal with PICI to expand immunotherapy development.
- Bayer's BlueRock inks cardiovascular cell therapy delivery deal.
- Neurocrine Biosciences to acquire Diurnal.
- Boston Scientific bulks up blood-blocking portfolio with Obsidio acquisition.
- Valo Therapeutics acquires PeptiCHIP technology.
- Evotec Biologics and Alpine Immune Sciences expand partnership.
- Chugai and Noile-Immune ink CAR-T licensing deal.
Updates at Aagami: - Aagami to attend BIO-Europe® 2022 (October 24–26, 2022 | Leipzig, Germany).
- Aagami received another contract extension from an existing client.
INFOCUS: Select opportunities available at Aagami: For Acquisition: - Available at a very reasonable price Mountain View Pharma (MVP) including its PharmaPEG® technology, product candidates, data package of ~20 drug candidates, IP etc.- for Next-generation biologics and substantial returns.
For Partnering/Licensing/ Investment:
- Technology Licensing: Easy to apply Microneedle Array Patch (MAP) system to deliver drugs, vaccines; better immune response than injection. A painless and efficient replacement to Syringes.
- Investment / Licensing - US FDA approved portable MRI Guided Treatment, Diagnosis and Screening ($40 Million Series C Open). For Urology applications.
- Series B Open- Novel Evolution of Portable MRI and Robotics for Neurology treatments like Strokes and TBI.
- Midwest US based Pharma’s First-in-Class Non-Opioid Analgesic for both chronic and acute Pain Relief – Seeking funding/licensing/co-development partnerships.
|